Role of calcium in postjunctional supersensitivity.

Several hours to days after an animal is given reserpine its cardiovascular system becomes supersensitive to catecholamines. This phenomenon can be demonstrated for vascular tissue by in vitro experiments. This type of supersensitivity has been termed "nonspecific" because the tissue is supersensitive to varied agonists, including acetylcholine, calcium, potassium, and the catecholamines. Animals that have been treated with reserpine have been found to have a transient decrease in the calcium content of their vascular tissue. The responses to norepinephrine of aortic strips from reserpine-treated rabbits, even though of greater magnitude than those of untreated aortic strips, were less dependent on extracellular calcium than responses of strips from untreated rabbits. On the other hand, the responses to potassium were more dependent on extracellular calcium. In addition, when aortic strips from reserpine-pretreated animals are subjected to potassium in a calcium-free medium, they are not supersensitive to the ion. When aortic strips are placed in a calcium-free, depolarizing medium they are still supersensitive to norepinephrine and isoproterenol but not to acetylcholine. Tension decline and 45Ca efflux studies suggest that reserpine-treated tissues retain longer than untreated tissues a calcium fraction involved in contraction. It is concluded that reserpine alters binding or movement of calcium in at least two sites. The lack of supersensitivity to acetylcholine and potassium in a calcium-free medium indicates an effect of reserpine (or the loss of adrenergic transmitter) on the utilization of extracellular calcium, while some other site must be involved in at least part of the supersensitivity to the catecholamines.     

Electrophysiological correlations with postjunctional supersensitivity.

Several lines of evidence have been found which suggest that a partial depolarization is an important event in the development of postjunctional (nondeviation) supersensitivity in the vas deferens and atrium. In the vas deferens of the guinea pig, experiments with microelectrodes indicate that a depolarization of approximately 10 mV occurs after denervation or decentralization. The time course of the depolarization is the same as the time course of the development of supersensitivity found 7 days after denervation in the rat vas deferens. An analysis of the magnitude of junction potentials in the vas deferens supports the conclusion that changes in adrenergic receptors are not a significant factor in postjunctional supersensitivity. An analysis of membrane potential in guinea pig atria demonstrates a high correlation between the appearance of supersensitivity and a partial depolarization in that tissue alsomit is suggested that chronic interruption of the innervation to smooth or cardiac muscle leads to an alteration in the binding of calcium to the cell membrane and a consequent depolarization. The result is a resting membrane potential closer to the threshold for excitation.     

Effects of age on the adrenergic cardiac neuroeffector junction

Although it is clear that adrenergic nervous system control of cardiac function decreases with age and that the effector organ fails to adjust to this decreased control, it is not completely evident which of the many mechanisms operant at the adrenergic-cardiac neuroeffector junction contribute to this state. Prejunctionally, it appears that norepinephrine content decreases with age and that adrenergic axonal degeneration occurs. Also, evidence is available to suggest that modulation by prejunctional alpha adrenergic receptors of norepinephrine release is altered with increasing age, as is neuronal uptake of norepinephrine. Postjunctionally, it appears that beta-adrenergic receptor sensitivity to agonists undergoes age-related alterations, and possibly post receptor mechanisms involved in receptor-response coupling. Other mechanisms, such as those involved in transmitter uptake into extraneuronal sites, adrenergic neuronal responsiveness to stimulation, transmitter release and turnover, calcium and prejunctional receptor modulation of transmitter release, postjunctional receptor development of supersensitivity or subsensitivity, need further elucidation in order to have an understanding of the factors that contribute to the breakdown of homeostatic mechanisms that regulate the heart.     

Potentiation by supernatant of Ca2+ uptake in rabbit aortic microsomes: effect of pretreatment of animals with reserpine

The effect of 105,000 g supernatant on Ca²⁺ uptake by rabbit aortic microsomes was studied to determine if a membrane-cytosol interaction exists, and to determine whether it is modified by pretreatment of animals with reserpine, which induces postjunctional supersensitivity in this tissue. Aliquots of supernatant from aortae of control and pretreated animals potentiated ATP-dependent microsomal Ca²⁺ uptake nearly equally but had no effect on total ATPase. Uptake-potentiation in control microsomes was significant only in the presence of 5 mM oxalate, whereas uptake-potentiation in reserpine-pretreated microsomes was significant both in the absence or presence of oxalate. A cytosolic factor in smooth muscle cells may be involved in Ca²⁺ transport in a manner reported for erythrocytes. Its action appears to be unmodified by reserpine-pretreatment. Instead, an alteration in the microsomes affects the interaction of the Ca²⁺ transport mechanism with the cytosolic factor.     

The effect of antidepressants on the calcium content of the aorta of reserpine-treated rabbits.

The pre-administration of reserpine in a dose of 5 mg/kg b.o. i.v. 24 before the experiment reduced the calcium content of the thoracic aorta of rabbits weighing 1,000--1,500 g. It had no effect on the calcium level in older animals. The calcium content also fell after 10 days' administration of reserpine in daily doses of 0.1 mg/kg b.w. Pre-administration of the monoaminooxidase inhibitors phenelsine and nialamide inhibited the reserpine-induced decrease in the calcium content of the vascular wall, although by themselves they had no effect on it. Prothiadene, a thymoanaleptic, likewise inhibited, the decrease in the calcium content when administered per os in a dose of 5 mg/kg b.w. 5 hours before reserpine.     

Reserpine-induced hypothermia and its reversal by dopamine agonists

Prior treatments with reserpine altered the thermic response of mice to subsequently administered apomorphine and amphetamine. Thus, normal mice exhibited hypo- and hyper-thermic responses to apomorphine and (+)-amphetamine, respectively but did not respond to (-)-amphetamine. These responses were each readily attenuated by haloperidol. Reserpinized mice, on the other hand, exhibited hyperthermic responses to all three agonists and these responses were not attenuated by haloperidol. In addition to its hypothermic action, reserpine also produced hypoactivity which was reversed by (+)-amphetamine. This reversal of hypoactivity was attenuated by haloperidol. These data suggest that reversal of reserpine-induced hypothermia by dopamine agonists results through activation of mechanisms which are separate from those normally associated with agonist-induced thermic responses. Reversal of hypoactivity, on the other hand, appears to be due to reactivation of those systems which normally regulate locomotor activity.     

Morphological and biochemical changes in supersensitive smooth muscle.

The effect of postganglionic denervation on the incidence of nexal contacts in the smooth muscle of the rat vas deferens was investigated. The chronically denervated tissue exhibited twice as many nexuses as control. This increase in the incidence of cell contacts may contribute to the supersensitivity and/or the increase in maximum response of the denervated vas deferens. The effects of denervation, decentralization, and pretreatment with reserpine on the concentration of adenosine triphosphate (ATP) in vasa deferentia of rats and guinea pigs were also investigated. One day after denervation there was a substantial decrease in the endogenous norepinephrine and ATP concentrations. The norepinephrine concentration remained low (less than 10% of control) throughout subsequent days (up to 14 days) whereas the ATP concentration, after the first postoperative day, rose significantly. The rise in ATP concentration was temporally correlated with the development of postjunctional supersensitivity. Decentralization and pretreatment with reserpine both resulted in a significant increase in ATP concentration which preceded by 2 to 3 days a significant increase in sensitivity of the vas deferens. It appears that a change in the tissue concentration of ATP may be one of the initial events that occurs following interruption of the neural contact to the smooth muscle of the vas deferens.     

The effect of adrenal cortical hormones on the calcium content of rat aorta.

The administration of prednisone in a dose of 10 mg/kg b.w. per os and of deoxycorticosterone in a dose of 10 mg/kg i.p. to rats weighing 200--220 g 24 hours before the experiment did not affect significantly the calcium content of the aortic vascular tissue. Metopiron, which influences biosynthesis of the adrenal hormones, likewise did not affect the calcium content when administered i.p. in a dose of 500 mg/kg b.w. and did not inhibit reserpine-induced calcium depletion. The results thus failed to confirm the hypothesis that reserpine influences the calcium content of the vascular wall via stimulation of corticold release.     

An increase in putative voltage dependent calcium channel number following reserpine treatment

Rats were treated with reserpine (0.2 mg/kg) on days 1, 3, and 5. On day 6, binding parameters for alpha-1 adrenergic receptors (3H-prazosin) and putative voltage dependent calcium channels, VDCC (3H-nitrendipine), were determined. There was an increase in both the number (2.1 fold) and affinity (1.8 fold) of alpha-1 adrenergic receptors following reserpine treatment. In addition, there was a 2.7 fold increase in the number of VDCCs, but no change in VDCC binding affinity, following reserpine treatment. These data are consistant with the development of smooth muscle supersensitivity following reserpine treatment in a variety of tissues, and suggest that VDCC number may be modulated by the cell in response to tonic levels of catecholamines. Changes in the number of VDCCs may be an important regulatory mechanism for cell function in physiologic and pathologic states.     

Protective effect of nebivolol on reserpine-induced neurobehavioral and biochemical alterations in rats

Reserpine-induced orofacial dyskinesia is a model that shares some mechanists’ aspects with tardive dyskinesia whose pathophysiology has been related to oxidative stress. The present study was aimed to explore neuroprotective effects of nebivolol, an antihypertensive agent, on reserpine-induced neurobehavioral and biochemical alterations in rats. Reserpine (1 mg/kg, s.c.) was used to induce neurotoxicity. Administration of reserpine for 3 days every other day significantly increased the vacuous chewing movements (VCMs), tongue protrusions (TPs) and reduced the locomotor activity in rats. Pre-treatment with nebivolol (5 and 10 mg/kg, p.o. for 5 days) showed dose dependant decrease in VCMs and TP induced by reserpine. Nebivolol also showed significant improvement in locomotor activity. Reserpine significantly increased lipid peroxidation and reduced the levels of defensive antioxidant enzymes like catalase (CAT), superoxide dismutase (SOD) and reduced glutathione (GSH) in rat brain. Nebivolol reversed these effects of reserpine on oxidative stress indices; indicating amelioration of oxidative stress in rat brains. The results of the present study indicated that nebivolol has a protective role against reserpine-induced orofacial dyskinesia. Thus, the use of nebivolol as a therapeutic agent for the treatment of tardive dyskinesia may be considered.     

Enhancement of reserpine-elicited dopaminergic supersensitivity by repeated treatment with apomorphine and alpha-methyl-p-tyrosine.

Pretreatment of rats with reserpine 5 mg/Kg/day for 2 days elicits an enhanced stereotyped response following injection of apomorphine or amphetamine which persists through the 17th day. Since apomorphine acts as a direct postsynaptic receptor agonist in dopaminergic neurons this effect may represent a postsynaptic supersensitivity. In an attempt to prevent the development of supersensitivity apomorphine was administered repeatedly during the reserpinization period. Contrary to expectations a further enhancement of supersensitivity was seen when animals were challenged days later with apomorphine. This may be the result of presynaptic dopamine-synthesis-inhibition following apomorphine. Apomorphine-induced enhancement of reserpine supersensitivity was not seen in animals challenged with amphetamine. Alpha-methyl-para-tyrosine, but not scopolamine, repeatedly administered during the reserpinization mimics the effect of apomorphine, supporting the concept that the potentiating effects of apomorphine are mediated presynaptically. Furthermore it is suggested that the direct presynaptic action of apomorphine, and not that mediated via cholinergic interneurons, is operant in the development of enhanced supersensitivity.     

Animal model for cystic fibrosis: pulmonary clearance of Staphylococcus aureus in mice treated with reserpine.

Since it has been demonstrated that chronic administration of reserpine to rats produces CF-like alterations, we have studied the lung resistance to bacterial infections in animals treated with reserpine. Mice of the BALB/c inbred strain were injected subcutaneously with different doses of reserpine for 7 days; after, they were submitted to an infective aerosol containing $\text{Staphylococcus aureus}$ in a nebulization chamber. With each pair of exposed animals, an individual value of the uncleared bacteria ratio (UBR) at 4 hours was obtained. Reserpinized animals showed a significant increase in UBR values when compared to control mice (p < 0.05 and p < 0.01 depending on the doses), suggesting an impairment of the lung antibacterial defenses. Although pharmacological doses of reserpine produce catecholamine depletion, we can not conclude that this action upon the nervous system is the only cause of the CF-like response we detected. In conclusion, the observed UBR decrease lends support to the concept of a reserpine-induced CF animal model.     

Reserpine-induced immunocytochemical change of neuropeptide Y in the hypothalamic arcuate nucleus

The effect of reserpine on neuropeptide Y immunoreactive (NPY-IR) neurons in the rat hypothalamic arcuate nucleus was examined by immunocytochemical techniques. Although only NPY-IR fibers and terminals were distributed in this nucleus in untreated and saline treated rats, single treatment of reserpine (10 mg/kg, i.p.) visualized abundant NPY-IR neuronal cell bodies: the increase began at 12 h of postinjection, reached its maximal level at 48 h, and returned to its normal level at 96 h. Pretreatment of nialamide, a monoamine oxidase inhibitor, prevented these acute reserpine-induced changes, suggesting reserpine acts on NPY neurons through monoaminergic mechanism. Chronic treatment of haloperidol (5 mg/kg, once daily for 5 days) a dopamine receptor antagonist, could induce the similar increase of NPY immunoreactivity. However, interruption of adrenergic and serotonergic neurotransmissions by chronic treatment of propranorol and methysergide, or chemical lesions of ascending noradrenergic and serotononergic pathways by 6-hydroxydopamine and 5,6-dihydroxytryptamine, could not induce any immunoreactive increase of NPY in arcuate neurons. These findings strongly suggest that reserpine-induced NPY increase occurs through dopaminergic afferents in hypothalamic arcuate neurons. Special issue dedicated to Dr. Kinya Kuriyama.     

Abrogation of alpha-adrenergic vasoactivity in chronically inflamed rat knee joints

It has previously been shown that chronic inflammation causes a reduction in sympathetic nerve-mediated vasoconstriction in rat knees. To determine whether this phenomenon is due to an alteration in smooth muscle adrenoceptor function, the present study compared the alpha-adrenoceptor profile of blood vessels supplying the anteromedial capsule of normal and chronically inflamed rat knee joints. While the rats were under urethan anesthesia, the alpha(1)-adrenoceptor agonists methoxamine and phenylephrine and the alpha(2)-adrenoceptor agonist clonidine (0.1-ml bolus; dose range 10(-12)-10(-7) mol) were applied to exposed normal rat knees, resulting in a dose-dependent fall in capsular perfusion. Comparison of drug potencies indicated that alpha(2)-adrenergic effects > alpha(1)-vasoactivity. One week after intra-articular injection of Freund's complete adjuvant to induce chronic joint inflammation, the vasoconstrictor effects of methoxamine, phenylephrine, and clonidine were all significantly attenuated compared with normal controls. These findings show that the preponderance of sympathetic adrenergic vasoconstriction in the anteromedial capsule of the rat is carried out by postjunctional alpha(2)-adrenoceptors. Chronic joint inflammation compromises alpha(1)- and alpha(2)-adrenoceptor function, and this change in alpha-adrenergic responsiveness may help explain the perfusion changes commonly associated with inflammatory arthritis.     

Adrenergic pharmacology of human and canine peripheral veins

A comparison has been made of the factors concerned with the response of canine and human saphenous veins to adrenergic stimulation. Both vessels have prejunctional muscarinic and beta-adrenergic receptors. When activated by appropriate agonists these receptors decrease and increase the output, respectively, of norepinephrine from the nerve endings. Both vessels have postjunctional alpha 1 and alpha 2 adrenoceptors and postjunctional beta adrenoceptors. Activation of the former two receptors leads to contraction of the smooth muscle, and of the latter to relaxation. There are, however, qualitative differences. In the human veins the responsiveness of the prejunctional beta adrenoceptors exceeds that of the postjunctional, whereas the reverse is true in the dog. As a consequence, in the human vein beta-adrenergic agonists augment, and in the canine veins they depress, the contractile response to sympathetic nerve stimulation.     

Reserpine Increases Chromaffin Cell Enkephalin Stores Without a Concomitant Decrease in Other Proenkephalin-Derived Peptides

Reserpine increases the levels of enkephalins in adrenal medullary chromaffin cells; however, the origin of the newly apparent pentapeptides has been the subject of debate, because no increase in the levels of proenkephalin mRNA has been observed. The present study was performed for determining if the reserpine-induced increase in context of enkephalins was derived from processing of preexisting fragments of proenkephalin. Bovine chromaffin cell enkephalins and larger enkephalin-containing peptides were separated by reversed-phase HPLC and identified by approximate molecular weight, elution with peptide standards, and enkephalin sequences contained. Treatment of the cells with reserpine increased the levels of enkephalins and of enkephalin-containing peptides of up to approximately 3 kilo-daltons without reducing the levels of larger enkephalin-containing peptides. Similar results were obtained with another catecholamine-depleting drug, tetrabenazine. In contrast, treatment of chromaffin cells with theophylline or forskolin increased the levels of both enkephalins and enkephalin-containing peptides of all sizes. The results suggest that new synthesis of proenkephalin is required for the effects of reserpine, although proenkephalin processing is also altered by this drug.     

Demonstration of denervation supersensitivity: a pharmacological approach

1. Although the phenomenon of denervation supersensitivity has been extensively studied in peripheral cholinergically and adrenergically innervated organs, the consequences of denervation have not been studied in as much detail in serotonergically innervated s stems. This may be due in part to the difficulties associated with producing specific lesions of serotonergic systems and with quantifying physiological responses of the CNS due to serotonin. 2. Because the lateral ciliated cells of the gill of the bivalve mollusc, Mytilus edulis, are innervated by serotonergic motor neurons which are responsible for accelerating the beating rate of the cilia we used this as a model system with which to study the effects of denervation by physical transections of the branchial nerve and by pharmacological treatments with 5,6 dihydroxytryptamine. 3. Both treatments produced a supersensitive response of the ciliated cells to the superfusion of serotonin. Two mechanisms with different time courses may be responsible. 4. The initial faster acting component may be due to changes in re-uptake mechanisms for serotonin, while the later slowly developing component may be due to other causes, including a hyperplasia of postjunctional serotonin receptors.     

Further evidence for an involvement of nociceptin/orphanin FQ in the pathophysiology of Parkinson's disease: a behavioral and neurochemical study in reserpinized mice

The contribution of nociceptin/orphanin FQ (N/OFQ) to reserpine-induced Parkinsonism was evaluated in mice. A battery of motor tests revealed that reserpine caused dose-dependent and long-lasting motor impairment. Endogenous N/OFQ sustained this response because N/OFQ peptide (NOP) receptor knockout (NOP(-/-) ) mice were less susceptible to the hypokinetic action of reserpine than wild-type (NOP(+/+) ) animals. Microdialysis revealed that reserpine elevated glutamate and reduced GABA levels in substantia nigra reticulata, and that resistance to reserpine in NOP(-/-) mice was accompanied by a milder increase in glutamate and lack of inhibition of GABA levels. To substantiate this genetic evidence, the NOP receptor antagonist 1-[(3R,4R)-1-cyclooctylmethyl-3-hydroxymethyl-4-piperidyl]-3-ethyl-1,3-dihydro-2H benzimidazol-2-one (J-113397) simultaneously reduced akinesia and nigral glutamate levels in reserpinized NOP(+/+) mice, being ineffective in NOP(-/-) mice. Moreover, repeated J-113397 administration in reserpinized mice resulted in faster recovery of baseline motor performance which was, however, accompanied by a loss of acute antiakinetic response. The short-term beneficial effect of J-113397 was paralleled by normalization of nigral glutamate levels, whereas loss of acute response was paralleled by loss of the ability of J-113397 to inhibit glutamate levels. We conclude that endogenous N/OFQ contributes to reserpine-induced Parkinsonism, and that sustained NOP receptor blockade produces short-term motor improvement accompanied by normalization of nigral glutamate release.     

Effect of BR-16A (Mentat), a polyherbal formulation on drug-induced catalepsy in mice

Parkinson's disease (PD) is a neurodegenerative disease characterized by the selective loss of dopamine (DA) neurons of the substantia nigra pars compacta (SNc). The events, which trigger and/or mediate the loss of nigral DA neurons, however, remain unclear. Neuroleptic-induced catalepsy has long been used as an animal model for screening drugs for Parkinsonism. Administration of haloperidol (1 mg/kg, ip) or reserpine (2 mg/kg, ip) significantly induced catalepsy in mice. BR-16A (50 and 100 mg/kg, po), a polyherbal formulation or ashwagandha (50 and 100 mg/kg, po), significantly reversed the haloperidol or reserpine-induced catalepsy. The results indicate that BR-16A or ashwagandha has protective effect against haloperidol or reserpine-induced catalepsy and provide hope that BR-16A could be used in preventing the drug-induced extrapyramidal side effects and may offer a new therapeutic approach to the treatment of Parkinson's disease.     

Generalised smooth-muscle disease with defective muscarinic-receptor function.

A patient with widespread smooth-muscle disease presented with chronic intestinal pseudo-obstruction but had in addition defects of the bladder, pupils, sweating, and cardiovascular function. There was no evidence of a primary neural lesion, and minor changes in the muscle did not resemble those of a myopathy. In each organ affected muscarinic cholinergic function was at fault, but instead of supersensitivity to cholinergic drugs, which occurs in postganglionic autonomic neuropathies, there was a lack of response to cholinergic drugs and anticholinesterases. It was therefore concluded that the patient had a new type of defect of muscarinic-receptor function. The cause was unknown, but it may have been an autoimmune disease resembling myasthenia, in which there is a postjunctional defect of muscarinic receptors. In similar cases binding of muscarinic agonists and antagonists should be tested. When antibodies to purified human muscarinic receptors become available different patterns of smooth-muscle defect may be identifiable, enabling the lesion to be defined more precisely.